Comparison of Daclizumab HYP and Avonex® in Multiple Sclerosis

• Register: EUCTR
• Last refreshed on: 23 February 2015
• Main ID: EUCTR2009-012500-11-IE
• Date of registration: 07/01/2010
• Prospective Registration: Yes
• Primary sponsor: Biogen Idec Ltd
• Public title: Comparison of Daclizumab HYP and Avonex® in Multiple Sclerosis
• Scientific title: Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon ß 1a) in Patients with Relapsing-Remitting Multiple Sclerosis - DECIDE
• Date of first enrolment: 12/04/2010
• Target sample size: 1800
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012500-11
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 2

Countries of recruitment

Argentina, Australia, Brazil, Canada, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Mexico, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, United States

Contacts

• Name: Clinical trial information desk
• Affiliation: Biogen Idec

• Name: Clinical trial information desk
• Affiliation: Biogen Idec

Key inclusion & exclusion criteria

Inclusion criteria:
1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
2. Must be 18 to 55 years of age, inclusive, at the time of consent.
3. Must have a confirmed diagnosis of RRMS according to McDonald criteria, numbers 1 through 4 (Polman et al, 2005), and a cranial MRI demonstrating lesion(s) consistent with MS (it is not necessary to obtain a current scan if a scan performed previously is available; if a previous scan is not available, then the baseline scan may be used).
4. Must have a baseline EDSS between 0.0 and 5.0, inclusive.
5. Must meet one of the following disease activity-related criteria:
a) Two or more clinical relapses within the previous 3 years with at least 1 clinical relapse in the 12 months prior to randomization.
OR
b) One or more clinical relapses and 1 or more new MRI lesions (Gd+ and/or T2 hyperintense lesion) within the previous 2 years with at least one of these events in the 12 months prior to randomization. The new MRI lesion must be distinct from one associated with the clinical relapse. The baseline MRI may be used to satisfy this criterion.
Note: For inclusion purposes, a clinical relapse is defined as neurologic signs and/or symptoms documented in the medical record of at least 24 hours duration that are determined by the Investigator or the Treating Neurologist as consistent with an MS relapse. Time since relapse should be measured from the time of relapse onset. When inclusion is based on a new MRI lesion, activity must be verified by the central MRI reading center.
6. Women of childbearing potential must be willing to practice effective contraception during the study and be willing and able to continue contraception for 4 months after their last dose of study treatment.

Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1800
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion criteria:
1.Diagnosis of primary progressive, secondary progressive,or progressive relapsing MS (as defined by Lublin and Reingold, 1996).
2.Known intolerance, contraindication to, or history of non compliance with Avonex 30 mcg.3.History of malignancy; however, subjects with a history of excised or treated basal cell carcinoma or fewer than 3 squamous cell carcinomas are eligible to participate in this study.4.History of severe allergic or anaphylactic reactions.
5.Known hypersensitivity to study drugs or their excipients. 6.History of abnormal laboratory results that are indicative of any significant cardiac,endocrine, hematological, hepatic, immunologic, metabolic, urologic,pulmonary, gastrointestinal, dermatologic, psychiatric, renal,
neurological (other than MS), and/or other major disease that would
preclude administration of DAC HYP or Avonex.7.History of human
immunodeficiency virus (HIV) or other immunodeficient conditions.
8.History of drug or alcohol abuse within the 2 years prior to
randomization.9.History of seizure disorder or unexplained blackouts OR history of a seizure within 6 months prior to Baseline. 10.History of
suicidal ideation or an episode of clinically severe depression within 3
months prior to Day 1. Subjects receiving ongoing antidepressant
therapy will not be excluded from the study unless the medication has
been increased within the 6 months prior to Baseline.11.An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to
randomization.12.Known history of, or positive screening test result for hepatitis C virus or hepatitis B virus. 13.Varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before
screening.14.Exposure to varicella zoster virus within 21 days before
screening.15.Any of the following abnormal blood tests at screening:
• hemoglobin =9.0 g/dL• platelets =100 x 10^9/L• lymphocytes =1.0 x 10^9/L• neutrophils =1.5 x 10^9/L• alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT), aspartate aminotransferase/serum glutamic oxaloacetic
transaminase (AST/SGOT), or gamma glutamyl-transferase =2 times the upper limit of normal (ULN)• serum creatinine =ULN 16.Any previous treatment with daclizumab or other anti-CD25
monoclonal antibody.17.Any type of live virus vaccine from 4 weeks
before randomization.18.Infection requiring hospitalization or
intravenous (IV) antibiotics within 8 weeks before randomization.
19.Elective surgery performed from 2 weeks prior to randomization or
scheduled through end of the study.20.Treatment with another investigational drug or approved therapy for investigational use within the 6 months prior to randomization. 21.Prior treatment with the any of the following:• total lymphoid irradiation• cladribine• T cell or T cell receptor vaccination• any therapeutic monoclonal antibody, except natalizumab 22.Prior treatment with mitoxantrone, cyclophosphamide, fingolimod, or natalizumab within 1 year prior to randomization.23.Prior treatment with any of the following within the 6 months prior to randomization: • cyclosporine• azathioprine• methotrexate• mycophenolate mofetil•intravenous immunoglobulin • plasmapheresis or cytapheresis.24.Treatment with any of the following medications within the 30 days prior to randomization:• IV corticosteroid treatment• oral corticosteroid treatment• glatiramer acetate 25.Initiation of treatment or dose adjustment of commerc

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Relapsing-remitting Multiple Sclerosis
MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders

Intervention(s)

Product Name: DACLIZUMAB HYP
Product Code: BIIB019
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Daclizumab
Current Sponsor code: BIIB019
Other descriptive name: Daclizumab HYP (DAC HYP)
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use

Trade Name: AVONEX
Pharmaceutical Form: Solution for injection
Other descriptive name: INTERFERON BETA-1A
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 30-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Intramuscular use

Primary Outcome(s)

Timepoint(s) of evaluation of this end point: Any relapses and time on study that occur up to Week
144

Secondary Objective: The secondary study objectives are to test the superiority of DAC HYP compared to IFN ß-1a in slowing functional decline and disability progression and maintaining quality of life in this subject population.

Main Objective: The primary study objective is to test the superiority of DAC HYP compared to IFN ß-1a in preventing MS relapse in subjects with relapsing remitting MS (RRMS).

Primary end point(s): • Annualized relapse rate (ARR)

Secondary Outcome(s)

Secondary end point(s): a) Number of new or newly-enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) over 96 weeks
b) Proportion of subjects with sustained disability progression defined by at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from baseline EDSS =1.0 that is sustained for 12 weeks or at
least a 1.5-point increase on the EDSS from baseline EDSS = 0 that is sustained for 12 weeks
c) Proportion of subjects who are relapse-free
d) Proportion of subjects with a =7.5 point worsening from baseline the MSIS-29 physical score at 96 weeks

Timepoint(s) of evaluation of this end point: a) Weeks 0, 24, 96, (and also 144/early termination)
b) Screening, weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132,
144/early termination (and also follow up visits 1 and 2, and
unscheduled relapse assessment
c) up to week 144 (end of study visit)
d) 96 weeks

Secondary ID(s)

205MS301

Source(s) of Monetary Support

Biogen Idec Ltd